Elsevier Announces 2008 Journal Impact Factor Highlights
Amsterdam, 29 June 2009 – Elsevier, the leading publisher of scientific, technical and medical information products and services, today announced the highlights of its journal impact factor performance in 2008. Elsevier overall saw 75% of its journal impact factors (IF) increase from 2007 to 2008. According to the 2008 Journal Citation Report® published by ThomsonReuters, Elsevier journals took the #1 position in 51 categories (of 229 in total) across all of the sciences and social sciences.
In addition, 30 Elsevier journals got their first IF this year. Some of these journals received very impressive scores including two Cell Press journals: Cell Stem Cell (16.826) entered the Cell Biology category ranked 6th (of 157 journals), while Cell Host & Microbe (7.436) entered the Microbiology category ranked10th (of 91 journals). Another impressive result in its first year is Materials Today (12.929), which is ranked 4th in the Materials Science, Multidisciplinary category (of 191 journals).
This year there were 182 Elsevier journals that increased their IF by more than 50% over their 2007 scores. All three The Lancetspeciality journals improved their IF this year. The Lancet Infectious Diseases increased to 13.165, placing it at the #1 position in the Infectious Diseases category. The Lancet Oncology (http://www.thelancet.com/journals/lanonc/issue/current) rose to 13.283, an increase of over 1 full IF point from the 2007 IF. Finally, The Lancet Neurology increased by 40% to 14.270, thereby retaining the #1 position in the Clinical Neurology category for the 5th year running.
Other Elsevier journals continue their long-running trend of increased IFs, in particular Biomaterials (increasing yearly since 2003) and The Journal of Allergy and Clinical Immunology which has shown consistent growth over the past five years.
Glen Campbell, Senior Vice President of U.S. Health Sciences Journals said, "Each annual announcement of impact factors confirms the depth and excellence of our health sciences journal publishing program. The superior performance of so many of our journals this year is a sign of the strong partnerships we have with our journal editors and our societies. This year's impact factor growth is one indication of the hard work and focus on quality of these collaborations."
“The fact that Elsevier’s overall results are amongst the best in the industry is a true indication of the impact of the increased focus on quality we have placed on our journals in the past three years. The increased impact factors, across the board, are evidence that the research we publish is of the highest quality,” remarked Martin Tanke, Managing Director of Science and Technology Journals. “We are grateful for our strong network of editors we partner with, who work with us each day to build our journals to some of the best in their fields.”
The impact factor is a measure of the frequency with which the average article in a journal has been cited in a particular year. The impact factor helps to evaluate a journal’s relative importance, especially when compared with others in the same field.
Elsevier is a world-leading provider of information solutions that enhance the performance of science, health, and technology professionals, empowering them to make better decisions, deliver better care, and sometimes make groundbreaking discoveries that advance the boundaries of knowledge and human progress. Elsevier provides web-based, digital solutions — among them ScienceDirect, Scopus, Elsevier Research Intelligence,and ClinicalKey—and publishes over 2,200 journals, including The Lancet and Cell, and over 33,000 book titles, including a number of iconic reference works.
The company is part of Reed Elsevier Group PLC, a world leading provider of professional information solutions in the Science, Medical, Legal and Risk and Business sectors, which is jointly owned by Reed Elsevier PLC and Reed Elsevier NV. The ticker symbols are REN (Euronext Amsterdam), REL (London Stock Exchange), RUK and ENL (New York Stock Exchange).
+31 20 485 2736